基线及系列分子分型预测MDS患者去甲基化治疗结局
研究对247例一线接受去甲基化药物(HMA)治疗的骨髓增生异常综合征(MDS)患者进行下一代测序(NGS)基线分子分型,并对其中108例系列测序。总体反应率42.1%,TET2突变/ASXL1野生型为最强反应预测因子;TP53、EZH2突变及突变数目与较差总生存(OS)独立相关,TP53突变清除与更优OS相关。
要点
- 基线NGS检测TP53、EZH2突变及突变数目可预测HMA治疗MDS的OS。
- TET2突变/ASXL1野生型基因型与最高总体反应率相关。
- HMA治疗中TP53突变清除与更优OS及移植结局相关。
核心结论
- 基线NGS分子分型支持用于HMA治疗的MDS患者,系列分型对TP53突变疾病有特殊价值。
研究设计与样本
- 247例一线HMA治疗的MDS患者进行基线NGS检测,其中108例在治疗期间系列测序。
主要发现
- 总体反应率42.1%,TET2突变/ASXL1野生型基因型总体反应率62.1%、完全缓解率34.5%。
- 中位OS为15个月;突变数目(HR 1.22;P=.02)、TP53突变(HR 2.33;P=.001)和EZH2突变(HR 2.41;P=.04)与较差OS独立相关。
- HMA治疗中TP53突变清除与更优OS相关(HR 0.28;P=.001),并改善后续接受异基因造血细胞移植患者的结局。
临床怎么用
- 对拟接受HMA治疗的MDS患者可考虑基线NGS检测TP53、EZH2等基因及突变数目以评估预后。
- 治疗中可考虑系列监测TP53突变状态,其清除提示更优生存及移植结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes (MDSs), yet identifying those patients unlikely to benefit remains challenging. We assessed response and overall survival (OS) in 247 patients molecularly profiled by next-generation sequencing (NGS) before first-line HMA therapy, and a subset of 108 patients were sequenced serially during treatment. The most common mutations included TP53 (33.1%), ASXL1 (19%), TET2 (16.5%), DNMT3A (14.1%), and SRSF2 (12.1%). The overall response rate was 42.1%, with the composite TET2-mutant/ASXL1 wild-type genotype representing the strongest predictor of response (overall response rate, 62.1%; complete remission rate, 34.5%). The median OS for the cohort was 15 months, and the number of mutations detected by NGS (hazard ratio [HR], 1.22; P = .02), as well as mutations in TP53 (HR, 2.33; P = .001) and EZH2 (HR, 2.41; P = .04) were identified as independent covariates associated with inferior OS in multivariable analysis. Serial molecular profiling revealed that clearance of TP53 mutations during HMA therapy was associated with superior OS (HR, 0.28; P = .001) and improved outcome in patients proceeding to allogeneic hematopoietic cell transplantation. These data support baseline molecular profiling by NGS in MDS patients treated with HMAs and provide novel observations of sequential profiling during therapy that provide particular value in TP53-mutated disease.
引用
- Hunter AM, Komrokji RS, Yun S, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021. PMID: 33591325. doi:10.1182/bloodadvances.2020003508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。